Characterization of Salvia Miltiorrhiza ethanol extract as an anti-osteoporotic agent

BMC Complementary and Alternative Medicine

Han-Jung Chae²  Hyung-Ryong Kim¹  Soo-Wan Chae²  Do-Sung Kim²  Bo Li²  Geum-Hwa Lee¹  Anu Marahatta²  Bidur Bhandary²  Yan Cui² 

[1]Department of Dental Pharmacology and Wonkwang Dental Research Institute, School of Dentistry, Wonkwang University, Iksan, Chonbuk, South Korea

[2]Department of Pharmacology and Institute of Cardiovascular Research, School of Medicine, Chonbuk National University, Jeonju, Chonbuk, South Korea

关键词: oxidative stress;    morphometry;    BMD;    OVX;    Salvia miltiorrhiza;   

Others  :  1232929
DOI  :  10.1186/1472-6882-11-120

 received in 2011-07-24, accepted in 2011-11-28,  发布年份 2011

【 摘 要 】

Background

Salvia miltiorrhiza (SM) has long been used as a traditional oriental medicine for cardiovascular disease. Accumulating evidence also indicates that SM has anti-osteoporotic effects. This study was conducted to examine the SM-induced anti-osteoporotic effect and its possible mechanisms with various doses of SM.

Methods

We studied Sprague-Dawley female rats aged 12 weeks, divided into six groups: sham-operated control (SHAM), OVX rats supplemented with SM (1, 3, 10 and 30 mg/kg) orally for 8 weeks. At the end of the experiment, blood samples were collected and biochemistry analysis was performed. Specimens from both tibia and liver were processed for light microscopic examination. DEXA and μ-CT analyses of the tibia were also performed.

Results

SM treatment significantly ameliorated the decrease in BMD and trabecular bone mass according to DEXA and trabecular bone architecture analysis of trabecular bone structural parameters by μ-CT scanning. In serum biochemical analysis, SM decreased the released TRAP-5b, an osteoclast activation marker and oxidative stress parameters including MDA and NO induced by OVX.

Conclusions

The preventive effect of SM was presumably due to its anti-oxidative stress partly via modulation of osteoclast maturation and number. In current study, SM appears to be a promising osteoporosis therapeutic natural product.

【 授权许可】

   
2011 Cui et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Anon.: Osteoporosis prevention, diagnosis, and therapy. Jama 2001, 285:785-795.
• [2]Vassilopoulou-Sellin R: Breast cancer and hormonal replacement therapy. Ann N Y Acad Sci 2003, 997:341-350.
• [3]Wang X, Morris-Natschke SL, Lee KH: New developments in the chemistry and biology of the bioactive constituents of Tanshen. Med Res Rev 2007, 27:133-148.
• [4]Han JY, Fan JY, Horie Y, Miura S, Cui DH, Ishii H, Hibi T, Tsuneki H, Kimura I: Ameliorating effects of compounds derived from Salvia miltiorrhiza root extract on microcirculatory disturbance and target organ injury by ischemia and reperfusion. Pharmacol Ther 2008, 117:280-295.
• [5]Zhou L, Zuo Z, Chow MS: Danshen: an overview of its chemistry, pharmacology, pharmacokinetics, and clinical use. J Clin Pharmacol 2005, 45:1345-1359.
• [6]Zhu YZ, Huang SH, Tan BK, Sun J, Whiteman M, Zhu YC: Antioxidants in Chinese herbal medicines: a biochemical perspective. Nat Prod Rep 2004, 21:478-489.
• [7]Kim HH, Kim JH, Kwak HB, Huang H, Han SH, Ha H, Lee SW, Woo ER, Lee ZH: Inhibition of osteoclast differentiation and bone resorption by tanshinone IIA isolated from Salvia miltiorrhiza Bunge. Biochem Pharmacol 2004, 67:1647-1656.
• [8]Zhang Y, Akao T, Nakamura N, Duan CL, Hattori M, Yang XW, Liu JX: Extremely low bioavailability of magnesium lithospermate B, an active component from Salvia miltiorrhiza in rat. Planta Med 2004, 70:138-142.
• [9]Lay IS, Chiu JH, Shiao MS, Lui WY, Wu CW: Crude extract of Salvia miltiorrhiza and salvianolic acid B enhance in vitro angiogenesis in murine SVR endothelial cell line. Planta Med 2003, 69:26-32.
• [10]Wong RW, Rabie AB: Effect of Salvia miltiorrhiza extract on bone formation. J Biomed Mater Res A 2008, 85:506-512.
• [11]Ding Y, Soma S, Takano-Yamamoto T, Matsumoto S, Sakuda M: Effects of salvia miltiorrhiza bunge (SMB) on MC3T3-E1 cells. J Osaka Univ Dent Sch 1995, 35:21-27.
• [12]Chae HJ, Chae SW, Yun DH, Keum KS, Yoo SK, Kim HR: Prevention of bone loss in ovariectomized rats: the effect of Salvia miltiorrhiza extracts. Immunopharmacol Immunotoxicol 2004, 26:135-144.
• [13]Brouwers JE, Lambers FM, Gasser JA, van Rietbergen B, Huiskes R: Bone degeneration and recovery after early and late bisphosphonate treatment of ovariectomized wistar rats assessed by in vivo micro-computed tomography. Calcif Tissue Int 2008, 82:202-211.
• [14]Jiang SD, Shen C, Jiang LS, Dai LY: Differences of bone mass and bone structure in osteopenic rat models caused by spinal cord injury and ovariectomy. Osteoporos Int 2007, 18:743-750.
• [15]Kim DS, Han SH, Lee YC, Park SJ, Yoo WH, Kim HR, Chae HJ: The study of the combination of Slavia Miltiorrhiza and Kitosan on osteoporosis in ovariectomized rats. Kor J Clin Pharm 2009, 19(2):75-80.
• [16]Jarvinen TL, Sievanen H, Kannus P, Jarvinen M: Dual-energy X-ray absorptiometry in predicting mechanical characteristics of rat femur. Bone 1998, 22:551-558.
• [17]Gothe S, Wang Z, Ng L, Kindblom JM, Barros AC, Ohlsson C, Vennström B, Forrest D: Mice devoid of all known thyroid hormone receptors are viable but exhibit disorders of the pituitary-thyroid axis, growth, and bone maturation. Genes Dev 1999, 13:1329-1341.
• [18]Kannus P, Jarvinen TL, Sievanen H, Kvist M, Rauhaniemi J, Maunu VM, Hurme T, Jozsa L, Järvinen M: Effects of immobilization, three forms of remobilization, and subsequent deconditioning on bone mineral content and density in rat femora. J Bone Miner Res 1996, 11:1339-1346.
• [19]Kastl S, Sommer T, Klein P, Hohenberger W, Engelke K: Accuracy and precision of bone mineral density and bone mineral content in excised rat humeri using fan beam dual-energy X-ray absorptiometry. Bone 2002, 30:243-246.
• [20]Draper HH, Hadley M: Malondialdehyde determination as index of lipid peroxidation. Methods Enzymol 1990, 186:421-431.
• [21]Bories PN, Bories C: Nitrate determination in biological fluids by an enzymatic one-step assay with nitrate reductase. Clin Chem 1995, 41:904-907.
• [22]Cremers S, Garnero P: Biochemical markers of bone turnover in the clinical development of drugs for osteoporosis and metastatic bone disease: potential uses and pitfalls. Drugs 2006, 66:2031-2058.
• [23]Halleen JM, Tiitinen SL, Ylipahkala H, Fagerlund KM, Vaananen HK: Tartrate-resistant acid phosphatase 5b (TRACP 5b) as a marker of bone resorption. Clin Lab 2006, 52:499-509.
• [24]Kireev RA, Tresguerres AC, Garcia C, Borras C, Ariznavarreta C, Vara E, Vina J, Tresguerres JA: Hormonal regulation of pro-inflammatory and lipid peroxidation processes in liver of old ovariectomized female rats. Biogerontology 2010, 11:229-243.
• [25]Van't Hof RJ, Ralston SH: Nitric oxide and bone. Immunology 2001, 103:255 261.
• [26]Sánchez-Rodríguez MA, Ruiz-Ramos M, Correa-Muñoz E, Mendoza-Núñez VM: Oxidative stress as a risk factor for osteoporosis in elderly Mexicans as characterized by antioxidant enzymes. BMC Musculoskelet Disord 2007, 19(8):124.
• [27]Koh JM, Lee YS, Kim YS, Kim DJ, Kim HH, Park JY, Lee KU, Kim GS: Homocysteine enhances bone resorption by stimulation of osteoclast formation and activity through increased intracellular ROS generation. J Bone Miner Res 2006, 21(7):1003-11.
• [28]Farley JR, Chesnut CH, Baylink DJ: Improved method for quantitative determination in serum of alkaline phosphatase of skeletal origin. Clin Chem 1981, 27:2002-2007.
• [29]Mosekilde L, Eriksen EF, Charles P: Effects of thyroid hormones on bone and mineral metabolism. Endocrinol Metab Clin North Am 1990, 19:35-63.
• [30]Mosekilde L, Melsen F, Bagger JP, Myhre-Jensen O, Schwartz Sorensen N: Bone changes in hyperthyroidism: interrelationships between bone morphometry, thyroid function and calcium-phosphorus metabolism. Acta Endocrinol (Copenh) 1977, 85:515-525.
• [31]Madsen JE, Aune AK, Falch JA, Hukkanen M, Konttinen YT, Santavirta S, Nordsletten L: Neural involvement in post-traumatic osteopenia: an experimental study in the rat. Bone 1996, 18:411-416.
• [32]Nilas L, Christiansen C: Rates of bone loss in normal women: evidence of accelerated trabecular bone loss after the menopause. Eur J Clin Invest 1988, 18:529-534.